These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 10760427)

  • 61. Toxicity of concurrent hyperfractionated radiation therapy and chemotherapy in locally advanced (stage III) non-small cell lung cancer (NSCLC): single institution experience in 600 patients.
    Jeremić B; Miličić B; Milisavljevic S
    Clin Transl Oncol; 2012 Aug; 14(8):613-8. PubMed ID: 22855143
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer.
    Sause WT; Scott C; Taylor S; Johnson D; Livingston R; Komaki R; Emami B; Curran WJ; Byhardt RW; Turrisi AT
    J Natl Cancer Inst; 1995 Feb; 87(3):198-205. PubMed ID: 7707407
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial.
    Dillman RO; Herndon J; Seagren SL; Eaton WL; Green MR
    J Natl Cancer Inst; 1996 Sep; 88(17):1210-5. PubMed ID: 8780630
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Patterns of care survey (PCS) in lung cancer: how well does current U.S. practice with chemotherapy in the non-metastatic setting follow the literature?
    Langer CJ; Moughan J; Movsas B; Komaki R; Ettinger D; Owen J; Wilson JF
    Lung Cancer; 2005 Apr; 48(1):93-102. PubMed ID: 15777975
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Concurrent cisplatin, etoposide, and radiotherapy for unresectable stage III nonsmall cell lung cancer: a phase II study.
    Reboul F; Brewer Y; Vincent P; Chauvet B; Faure CF; Taulelle M
    Int J Radiat Oncol Biol Phys; 1996 May; 35(2):343-50. PubMed ID: 8635942
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Treatment-related acute esophagitis for patients with locoregionally advanced non-small cell lung cancer treated with involved-field radiotherapy and concurrent chemotherapy.
    Bar-Ad V; Leiby B; Witek M; Xiao Y; Cui Y; Dai Y; Cao J; Axelrod R; Campling B; Both S; Werner-Wasik M
    Am J Clin Oncol; 2014 Oct; 37(5):433-7. PubMed ID: 23388558
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Does response to induction chemotherapy predict survival for locally advanced non-small-cell lung cancer? Secondary analysis of RTOG 8804/8808.
    McAleer MF; Moughan J; Byhardt RW; Cox JD; Sause WT; Komaki R
    Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):802-8. PubMed ID: 19540055
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Neoadjuvant chemotherapy followed by late-course accelerated hyperfractionated radiation therapy for locally advanced non-small-cell lung cancer: long-term results of a phase I/II clinical trial.
    Chen M; Chen YY; Bao Y; Xian CG; Liu GZ; Zhang L; Xu GC; Deng XW; Lu TX; Qian JY; Cui NJ
    Clin Lung Cancer; 2005 Mar; 6(5):304-9. PubMed ID: 15845182
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Daily low-dose cisplatin plus concurrent high-dose thoracic irradiation in locally advanced unresectable non-small-cell lung cancer: results of a phase II Southwest Oncology Group study.
    Hazuka MB; Crowley JJ; Bunn PA; O'Rourke M; Braun TJ; Livingston RB
    J Clin Oncol; 1994 Sep; 12(9):1814-20. PubMed ID: 8083705
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Hypofractionated Image-guided Radiation Therapy (3Gy/fraction) in Patients Affected by Inoperable Advanced-stage Non-small Cell Lung Cancer After Long-term Follow-up.
    Agolli L; Valeriani M; Bracci S; Nicosia L; DE Sanctis V; Enrici RM; Osti MF
    Anticancer Res; 2015 Oct; 35(10):5693-700. PubMed ID: 26408745
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Escalated hyperfractionated accelerated radiation therapy for locally advanced non-small cell lung cancer: a clinical phase II trial.
    Chen GY; Jiang GL; Qian H; Wang LJ; Yang HJ; Fu XL; Wu KL; Zang Z; Zhao S
    Radiother Oncol; 2004 May; 71(2):157-62. PubMed ID: 15110448
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Survival results and prognostic factors in T4 N0-3 non-small cell lung cancer patients according to the AJCC 7th edition staging system.
    Arslan D; Bozcuk H; Gunduz S; Tural D; Tattli AM; Uysal M; Goksu SS; Bassorgun Cİ; Koral L; Coskun HS; Ozdogan M; Savas B
    Asian Pac J Cancer Prev; 2014; 15(6):2465-72. PubMed ID: 24761848
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Time to treatment in patients with stage III non-small cell lung cancer.
    Wang L; Correa CR; Hayman JA; Zhao L; Cease K; Brenner D; Arenberg D; Curtis J; Kalemkerian GP; Kong FM
    Int J Radiat Oncol Biol Phys; 2009 Jul; 74(3):790-5. PubMed ID: 19231108
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Phase II study of pemetrexed and cisplatin, with chest radiotherapy followed by docetaxel in patients with stage III non-small cell lung cancer.
    Gadgeel SM; Ruckdeschel JC; Patel BB; Wozniak A; Konski A; Valdivieso M; Hackstock D; Chen W; Belzer K; Burger AM; Marquette L; Turrisi A
    J Thorac Oncol; 2011 May; 6(5):927-33. PubMed ID: 21415776
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Concurrent hyperfractionated irradiation and chemotherapy for unresectable nonsmall cell lung cancer. Results of Radiation Therapy Oncology Group 90-15.
    Byhardt RW; Scott CB; Ettinger DS; Curran WJ; Doggett RL; Coughlin C; Scarantino C; Rotman M; Emami B
    Cancer; 1995 May; 75(9):2337-44. PubMed ID: 7712445
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A phase II study of cisplatin and 5-fluorouracil with concurrent hyperfractionated thoracic radiation for locally advanced non-small-cell lung cancer: a preliminary report from the Okayama Lung Cancer Study Group.
    Segawa Y; Ueoka H; Kiura K; Kamei H; Tabata M; Sakae K; Hiraki Y; Kawahara S; Eguchi K; Hiraki S; Harada M
    Br J Cancer; 2000 Jan; 82(1):104-11. PubMed ID: 10638975
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Effect of different chemotherapy regimens for concurrent chemoradiotherapy on locally advanced non-small cell lung cancer].
    Ren H; Wang LH; Wang XZ; Lü JM; Ji W; Zhou ZM; Ou GF; Yin WB
    Zhonghua Zhong Liu Za Zhi; 2009 Feb; 31(2):143-7. PubMed ID: 19538894
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Dosimetric correlates for acute esophagitis in patients treated with radiotherapy for lung carcinoma.
    Bradley J; Deasy JO; Bentzen S; El-Naqa I
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1106-13. PubMed ID: 15001251
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
    Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
    Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Clinical prognostic factors in patients with locally advanced (stage III) nonsmall cell lung cancer treated with hyperfractionated radiation therapy with and without concurrent chemotherapy: single-Institution Experience in 600 Patients.
    Jeremić B; Miličić B; Milisavljevic S
    Cancer; 2011 Jul; 117(13):2995-3003. PubMed ID: 21692056
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.